{"id":"tocamphyl","rwe":[],"tags":[{"label":"tocamphyl","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":["NCT02263378","NCT04066816","NCT02333461","NCT03482401","NCT00455416","NCT04011618","NCT03535675","NCT02935777","NCT02056496","NCT07182370","NCT03713164"],"aliases":[],"patents":[],"pricing":[],"allNames":"gallogen","offLabel":[],"synonyms":["tocamphyl","gallogen","hepasynthyl","hepatoxane","lymethol","biliphorine","biliphorin"],"timeline":[],"approvals":[],"brandName":"Gallogen","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"tocamphyl","explanation":"Think of Gallogen like a key that fits into a lock in the body. When it binds to its target, it can either turn the lock on or off, depending on the specific pathway it's interacting with. This can have a range of effects, from blocking a harmful process to triggering a beneficial one.","oneSentence":"Gallogen works by interacting with a specific biological pathway, although the exact details of this interaction are unclear.","technicalDetail":"Gallogen's mechanism of action is thought to involve binding to a specific protein or receptor, although the precise molecular details of this interaction are currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2687","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TOCAMPHYL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:56:56.095147","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"tocamphyl","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02263378","phase":"NA","title":"Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.","status":"COMPLETED","sponsor":"University of Messina","isPivotal":false,"enrollment":60,"indication":"HPV Infection","completionDate":"2016-03"},{"nctId":"NCT04066816","phase":"NA","title":"Ellagic Acid, Urolithin and Colonic Microbial Communities Affected by Walnut Consumption","status":"COMPLETED","sponsor":"UConn Health","isPivotal":false,"enrollment":47,"indication":"Colo-rectal Cancer, Colon Cancer","completionDate":"2021-04-08"},{"nctId":"NCT02333461","phase":"NA","title":"Study to Evaluate Botanicals for Mechanisms Related to Appetite and Fat Metabolism in Healthy, Overweight and Obese Individuals","status":"COMPLETED","sponsor":"Access Business Group","isPivotal":false,"enrollment":90,"indication":"Overweight, Obesity","completionDate":"2012-08"},{"nctId":"NCT03482401","phase":"NA","title":"Metabolic Profiling of Dietary Polyphenols and Methylxanthines in Normal and Malignant Mammary Tissues From Breast Cancer Patients","status":"COMPLETED","sponsor":"National Research Council, Spain","isPivotal":false,"enrollment":40,"indication":"Breast Cancer","completionDate":"2019-12-31"},{"nctId":"NCT00455416","phase":"Phase 2","title":"Dietary Intervention in Stage III/IV Follicular Lymphoma. Impact on Markers of Cell Proliferation, Apoptosis, Host Immune Cell Infiltrate and Oxidative Stress.","status":"UNKNOWN","sponsor":"Oslo University Hospital","isPivotal":false,"enrollment":45,"indication":"Follicular Lymphoma","completionDate":"2009-12"},{"nctId":"NCT04011618","phase":"Phase 2","title":"Effect of Ellagic Acid Administration on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion","status":"UNKNOWN","sponsor":"University of Guadalajara","isPivotal":false,"enrollment":32,"indication":"Metabolic Syndrome","completionDate":"2022-12"},{"nctId":"NCT03535675","phase":"Phase 3","title":"A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostat","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":true,"enrollment":59,"indication":"Adenocarcinoma of the Prostate","completionDate":"2022-11-03"},{"nctId":"NCT02935777","phase":"Phase 1","title":"Investigation of the Acute Effect of Pomegranate Extract on Cognitive Function in Human Volunteers: A Double-blind, Placebo-controlled, Crossover Trial","status":"COMPLETED","sponsor":"Angela Stockton","isPivotal":false,"enrollment":20,"indication":"Mental Processes","completionDate":"2014-09"},{"nctId":"NCT02056496","phase":"Phase 1","title":"Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Gut Microbiota-derived Metabolites (Urolithins) in Overweight Subjects. Comparison Between Two Pomegranate Extracts","status":"COMPLETED","sponsor":"National Research Council, Spain","isPivotal":false,"enrollment":20,"indication":"Healthy","completionDate":"2014-02"},{"nctId":"NCT07182370","phase":"NA","title":"Polyphenol Metabolism and Personalized Nutrition in Menopause: Metabotypes, Microbiome-virome, and Relationship With Quality of Life and Cardiovascular Risk.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Research Council, Spain","isPivotal":false,"enrollment":90,"indication":"Menopause Related Conditions, Cardiovascular Risk","completionDate":"2027-08-31"},{"nctId":"NCT03713164","phase":"NA","title":"Exploratory Study to Determine the Bioavailability and Metabolism of Ellagic Acid From Pomegranate Juice vs. Pure Ellagic Acid","status":"COMPLETED","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":19,"indication":"Healthy","completionDate":"2018-09-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"001214","UNII":"9C8C4SBN10","CHEBI":"CHEBI:32237","INN_ID":"42","RXNORM":"60906","UMLSCUI":"C0168706","ChEMBL_ID":"CHEMBL4594221","KEGG_DRUG":"D01640","PUBCHEM_CID":"21853","MESH_SUPPLEMENTAL_RECORD_UI":"C074848"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gallogen is a small molecule with the synonyms TOCAMPHYL, TOCAMPHYL, and TOCANFILO. It has been studied in clinical trials for various conditions, including HPV infection, colorectal cancer, colon cancer, metabolic syndrome, and diet habits, often in combination with other substances such as ellagic acid and Annona muricata.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}